文献速递心血管MR

特征追踪整体纵向应变预测多中心缺血性与非缺血性扩张型心肌病患者死亡,且独立于射血分数与晚期钆增强

Feature-Tracking Global Longitudinal Strain Predicts Death in a Multicenter Population of Patients With Ischemic and Nonischemic Dilated Cardiomyopathy Incremental to Ejection Fraction and Late Gadolinium Enhancement.
PubMed 文献 · JACC Cardiovasc Imaging · 2018-01-17

本研究在4个美国医疗中心的1012例射血分数<50%的缺血性或非缺血性扩张型心肌病患者中,评估心脏磁共振特征追踪整体纵向应变(GLS)的预后价值。中位随访4.4年期间133例死亡,GLS每恶化1%与死亡风险增加89.1%相关(HR 1.891,P<0.001),且在缺血性与非缺血性亚组中均独立于射血分数和晚期钆增强。

要点

  • GLS每恶化1%,校正临床及影像危险因素(含EF和LGE)后死亡风险增加89.1%(HR 1.891,P<0.001)。
  • 加入GLS后模型C统计量由0.628升至0.867(P<0.0001),连续NRI为1.148(95%CI 0.996–1.318)。
  • 缺血性亚组GLS的HR为1.942(每1%,P<0.001),非缺血性亚组HR为2.101(每1%,P<0.001)。

核心结论

  • 心脏磁共振特征追踪GLS是多中心缺血性或非缺血性扩张型心肌病患者死亡的强独立预测因子,其预后价值增量于包括EF和LGE在内的常见临床与CMR危险因素。

研究设计与样本

  • 多中心队列研究,纳入4个美国医疗中心的连续患者,共1012例射血分数<50%的缺血性或非缺血性扩张型心肌病接受CMR检查者;GLS由3个长轴cine视图计算;主要终点为全因死亡;采用Cox比例风险回归及嵌套模型评估增量预后价值。

诊断标准与关键数值

  • GLS每恶化1%,校正临床和影像危险因素(含EF和LGE)后全因死亡风险HR为1.891(P<0.001)。
  • 缺血性扩张型心肌病亚组GLS每恶化1%的HR为1.942(P<0.001)。
  • 非缺血性扩张型心肌病亚组GLS每恶化1%的HR为2.101(P<0.001)。
  • Kaplan-Meier分析显示死亡风险随GLS三分位恶化显著增加(log-rank P<0.0001)。
  • 加入GLS后C统计量由0.628升至0.867(P<0.0001),连续NRI为1.148(95%CI 0.996–1.318)。

临床应用与阅片要点

  • 在缺血性或非缺血性扩张型心肌病且EF<50%的患者中,可基于3个长轴cine视图计算CMR特征追踪GLS以辅助死亡风险分层。
  • GLS提供的预后信息增量于EF和LGE,报告中可结合GLS三分位评估风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: The aim of this study was to evaluate the prognostic value of cardiac magnetic resonance (CMR) feature-tracking-derived global longitudinal strain (GLS) in a large multicenter population of patients with ischemic and nonischemic dilated cardiomyopathy.

BACKGROUND: Direct assessment of myocardial fiber deformation with GLS using echocardiography or CMR feature tracking has shown promise in providing prognostic information incremental to ejection fraction (EF) in single-center studies. Given the growing use of CMR for assessing persons with left ventricular (LV) dysfunction, we hypothesized that feature-tracking-derived GLS may provide independent prognostic information in a multicenter population of patients with ischemic and nonischemic dilated cardiomyopathy.

METHODS: Consecutive patients at 4 U.S. medical centers undergoing CMR with EF <50% and ischemic or nonischemic dilated cardiomyopathy were included in this study. Feature-tracking GLS was calculated from 3 long-axis cine-views. The primary endpoint was all-cause death. Cox proportional hazards regression modeling was used to examine the association between GLS and death. Incremental prognostic value of GLS was assessed in nested models.

RESULTS: Of the 1,012 patients in this study, 133 died during median follow-up of 4.4 years. By Kaplan-Meier analysis, the risk of death increased significantly with worsening GLS tertiles (log-rank p < 0.0001). Each 1% worsening in GLS was associated with an 89.1% increased risk of death after adjustment for clinical and imaging risk factors including EF and late gadolinium enhancement (LGE) (hazard ratio [HR]:1.891 per %; p < 0.001). Addition of GLS in this model resulted in significant improvement in the C-statistic (0.628 to 0.867; p < 0.0001). Continuous net reclassification improvement (NRI) was 1.148 (95% confidence interval: 0.996 to 1.318). GLS was independently associated with death after adjustment for clinical and imaging risk factors (including EF and late gadolinium enhancement) in both ischemic (HR: 1.942 per %; p < 0.001) and nonischemic dilated cardiomyopathy subgroups (HR: 2.101 per %; p < 0.001).

CONCLUSIONS: CMR feature-tracking-derived GLS is a powerful independent predictor of mortality in a multicenter population of patients with ischemic or nonischemic dilated cardiomyopathy, incremental to common clinical and CMR risk factors including EF and LGE.

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Romano S, Judd RM, Kim RJ, et al. Feature-Tracking Global Longitudinal Strain Predicts Death in a Multicenter Population of Patients With Ischemic and Nonischemic Dilated Cardiomyopathy Incremental to Ejection Fraction and Late Gadolinium Enhancement. JACC Cardiovasc Imaging. 2018. PMID: 29361479. doi:10.1016/j.jcmg.2017.10.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。